tradingkey.logo

Journey Medical Corp

DERM

7.010USD

+0.020+0.29%
Market hours ETQuotes delayed by 15 min
161.96MMarket Cap
LossP/E TTM

Journey Medical Corp

7.010

+0.020+0.29%
More Details of Journey Medical Corp Company
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.
Company Info
Ticker SymbolDERM
Company nameJourney Medical Corp
IPO dateNov 12, 2021
CEOMr. Claude Maraoui
Number of employees41
Security typeOrdinary Share
Fiscal year-endNov 12
Address9237 E Via De Ventura Blvd., Suite 105
CitySCOTTSDALE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code85258
Phone14804346670
Websitehttps://journeymedicalcorp.com/
Ticker SymbolDERM
IPO dateNov 12, 2021
CEOMr. Claude Maraoui
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
821.75K
+6.38%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
327.89K
+2.24%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+17.37%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+40.22%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
78.89K
+10.00%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
78.89K
+10.00%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
37.17K
+23.91%
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
821.75K
+6.38%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
327.89K
+2.24%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+17.37%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+40.22%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
78.89K
+10.00%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
78.89K
+10.00%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
By BusinessUSD
Name
Revenue
Proportion
Qbrexa
5.16M
39.28%
Accutane
3.65M
27.82%
Emrosi
2.07M
15.75%
Amzeeq
1.10M
8.37%
Other branded revenue
727.00K
5.53%
Zilxi
426.00K
3.24%
By RegionUSD
Name
Revenue
Proportion
United States
13.14M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Qbrexa
5.16M
39.28%
Accutane
3.65M
27.82%
Emrosi
2.07M
15.75%
Amzeeq
1.10M
8.37%
Other branded revenue
727.00K
5.53%
Zilxi
426.00K
3.24%
Shareholding Stats
Updated: Fri, Aug 1
Updated: Fri, Aug 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fortress Biotech Inc
19.43%
Tang Capital Management, LLC
10.72%
Wasatch Global Investors Inc
5.38%
Maraoui (Claude)
4.75%
The Vanguard Group, Inc.
2.15%
Other
57.56%
Shareholders
Shareholders
Proportion
Fortress Biotech Inc
19.43%
Tang Capital Management, LLC
10.72%
Wasatch Global Investors Inc
5.38%
Maraoui (Claude)
4.75%
The Vanguard Group, Inc.
2.15%
Other
57.56%
Shareholder Types
Shareholders
Proportion
Corporation
19.43%
Hedge Fund
12.91%
Individual Investor
11.46%
Investment Advisor
8.82%
Investment Advisor/Hedge Fund
6.78%
Insurance Company
1.04%
Research Firm
0.18%
Private Equity
0.16%
Other
39.22%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
93
10.18M
58.84%
-100.22K
2025Q1
89
9.75M
61.79%
-68.70K
2024Q4
83
8.33M
55.97%
-821.12K
2024Q3
84
6.72M
45.26%
-1.40M
2024Q2
79
7.11M
49.43%
-621.27K
2024Q1
70
6.34M
49.52%
-781.26K
2023Q4
68
5.80M
46.63%
-1.25M
2023Q3
54
6.63M
53.88%
+189.20K
2023Q2
50
5.90M
48.59%
-532.43K
2023Q1
47
7.46M
63.41%
-218.78K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fortress Biotech Inc
3.36M
19.43%
--
--
Apr 14, 2025
Tang Capital Management, LLC
1.85M
10.72%
+129.03K
+7.48%
Mar 31, 2025
Wasatch Global Investors Inc
930.60K
5.38%
+930.60K
--
Mar 31, 2025
Maraoui (Claude)
821.75K
4.75%
+49.28K
+6.38%
Jun 17, 2025
The Vanguard Group, Inc.
372.26K
2.15%
+47.09K
+14.48%
Mar 31, 2025
Rosenwald (Lindsay A)
320.71K
1.85%
-9.73K
-2.94%
Apr 14, 2025
Alloush (Ramsey)
316.68K
1.83%
+46.86K
+17.37%
Jun 17, 2025
Renaissance Technologies LLC
238.00K
1.38%
+2.00K
+0.85%
Mar 31, 2025
American Financial Group, Inc.
180.00K
1.04%
--
--
Mar 31, 2025
PVG Asset Management Corporation
174.38K
1.01%
+6.27K
+3.73%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
Royce Quant Small-Cap Quality Value ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.01%
Dimensional US Core Equity 1 ETF
Proportion0%
Royce Quant Small-Cap Quality Value ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI